Physician profile
Colleen Powers
NPI 1306475876
$10,264.70
in general payments reported to CMS, 2019-2025
35 companies · $3,164 in 2025
The $3,164 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $48.87 · 2021: $539 · 2022: $1,553 · 2023: $2,256 · 2024: $2,704 · 2025: $3,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,641 · Education: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,640.92 |
| Education | $483.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,787.81 | 2020-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $1,407.51 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $668.33 | 2021-2025 | |
| Janssen Biotech, INC. | $612.74 | 2021-2025 | Tremfya |
| Incyte Corporation | $593.09 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $476.99 | 2023-2024 | Vtama |
| Ucb, INC. | $475.56 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $422.97 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $393.11 | 2023-2025 | |
| Galderma Laboratories, L.P. | $392.75 | 2024-2025 | Nemluvio, Aklief, Twyneo |
| Leo Pharma INC. | $380.02 | 2021-2025 | Adbry, Anzupgo |
| Mallinckrodt Hospital Products INC. | $289.90 | 2023-2025 | Acthar, Uvadex |
| Sun Pharmaceutical Industries INC. | $261.17 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $246.34 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $238.17 | 2022-2025 | Dupixent |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $233.25 | 2022-2024 | Cabtreo, Arazlo, Duobrii |
| Janssen Scientific Affairs, LLC | $194.10 | 2022-2024 | Tremfya |
| Almirall LLC | $178.36 | 2024-2025 | Klisyri, Seysara |
| Organon LLC | $115.93 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.62 | 2023 | Spevigo |
| Amryt Pharma Holdings LTD | $105.63 | 2022 | |
| Kyowa Kirin, INC. | $103.86 | 2023 | Poteligeo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Revance Therapeutics, INC. | $96.77 | 2024-2025 | Daxxify |
| Arcutis Biotherapeutics, INC. | $70.21 | 2024-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $67.88 | 2021-2022 | |
| Botanix Sb INC | $48.92 | 2025 | Sofdra |
| Amgen INC. | $36.31 | 2022-2025 | Otezla |
| Biofrontera INC. | $34.01 | 2024-2025 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Mayne Pharma Commercial LLC | $29.35 | 2025 | |
| Journey Medical Corporation | $20.71 | 2025 | |
| Pierre Fabre Pharmaceuticals, INC. | $20.69 | 2022 | |
| Gilead Sciences, INC. | $20.34 | 2020 | |
| Stemline Therapeutics INC. | $17.72 | 2022 | |
| Convatec INC. | $16.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.